Please use this identifier to cite or link to this item: http://dx.doi.org/10.18419/opus-1794
Authors: Hauber, Wolfgang
Waldenmeier, Marc T.
Title: The AMPA antagonist GYKI 52466 reverses the anticataleptic effects of the competitive NMDA antagonist CGP 37849
Issue Date: 1994
metadata.ubs.publikation.typ: Zeitschriftenartikel
metadata.ubs.publikation.source: European Journal of Pharmacology 256 (1994), S. 339-342. URL http://dx.doi.org./10.1016/0014-2999(94)90561-4
URI: http://nbn-resolving.de/urn:nbn:de:bsz:93-opus-39646
http://elib.uni-stuttgart.de/handle/11682/1811
http://dx.doi.org/10.18419/opus-1794
Abstract: The effects of the AMPA receptor antagonist GYKI 52466 (1-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine HCl) on haloperidol-induced catalepsy were tested in drug-naive rats and in rats pretreated with the competitive NMDA receptor antagonist CGP 37849 (DL-(E)-2-amino-4-methyl-5-phosphono-3-pentenoic acid). CGP 37849 (4 mg/kg i.p.) given alone significantly reversed haloperidol-induced catalepsy (0.5 mg/kg i.p.) while GYKI 52466 (4.8 mg/kg i.p.) given alone was without effect. Administration of GYKI 52466 to rats pretreated with CGP 37849 abolished the anticataleptic effects of the competitive NMDA receptor antagonist seen following single administration. Thus the AMPA receptor antagonist prevents behavioural effects induced by a NMDA receptor antagonist in this behavioral model.
Appears in Collections:04 Fakultät Energie-, Verfahrens- und Biotechnik

Files in This Item:
File Description SizeFormat 
hau3.pdf302,79 kBAdobe PDFView/Open


Items in OPUS are protected by copyright, with all rights reserved, unless otherwise indicated.